Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

U.S. investigating Elon Musk's Neuralink over hazardous pathogens

Published 02/09/2023, 06:05 AM
Updated 02/09/2023, 01:17 PM
© Reuters. FILE PHOTO: Neuralink logo and Elon Musk photo are seen in this illustration taken, December 19, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

By Rachael Levy

(Reuters) -The U.S. Department of Transportation said on Thursday it is investigating Elon Musk's brain-implant company Neuralink over the potentially illegal movement of hazardous pathogens.

A Department of Transportation spokesperson told Reuters about the probe after the Physicians Committee of Responsible Medicine (PCRM), an animal-welfare advocacy group, wrote to Secretary of Transportation Pete Buttigieg earlier on Thursday to alert it of records it obtained on the matter.

PCRM said it obtained emails and other documents that suggest unsafe packaging and movement of implants removed from the brains of monkeys. These implants may have carried infectious diseases in violation of federal law, PCRM said.

The Department of Transportation spokesperson said the agency took PCRM's allegations "very seriously."

"We are conducting an investigation to ensure that Neuralink is in full compliance with federal regulations and keeping their workers and the public safe from potentially dangerous pathogens," the spokesperson said.

Representatives for Neuralink, including Musk, did not respond to comment requests.

The Department of Transportation probe adds to the scrutiny facing Neuralink, which is developing a brain implant it hopes will help paralyzed people walk again and cure other neurological ailments.

In December, Reuters reported that Neuralink has been under a federal investigation over potential animal welfare violations and that some of its staff made internal complaints about experiments being rushed, causing needless suffering and deaths.

The letter said records that the group obtained showed instances of pathogens, such as antibiotic-resistant staphylococcus and herpes B virus, that may have been transported without proper containment measures.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The incidents that involved potential breaches of hazardous material transportation regulations happened in 2019, when Neuralink relied on University of California, Davis to help carry out its experiments on primates, according to the documents cited by PCRM.

While Neuralink's partnership with UC Davis ended in 2020, PCRM said the company continues to employ the neurosurgeon who oversaw the experiments and other staff involved may also still be employed.

Reuters reviewed the UC Davis records cited by PCRM in its letter. It is unclear whether further records exist that provide a different or fuller account of what happened. PCRM obtained the records from UC Davis through public information requests. Neuralink messages and records not shared with UC Davis are not subject to such information requests.

A UC Davis spokesperson would only say that the university abides by all biohazard and lab safety regulations.

PCRM's letter said pathogens were carried on removed implants from monkeys after improper sanitization and packaging. The group said those pathogens could cause serious health issues in infected humans, such as bloodstream infections, pneumonia and severe brain damage, among other problems.

PCRM, which opposes the use of animals in medical research, did not identify any harm as a result of these incidents, but said Neuralink's actions "may pose a serious and ongoing public health risk."

"The company's documented track record of sloppy, unsafe laboratory practices compel DOT to investigate and levy appropriate fines," PCRM said in the letter.

PCRM said it also found instances that appear to describe UC Davis employees urging immediate biohazard training for Neuralink employees following incidents that had caused contamination concerns. On one occasion in April 2019, a UC Davis employee wrote in an email that the university’s primate center is “at risk” for “monkey contaminated hardware.”

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"This is an exposure to anyone coming in contact with the contaminated explanted hardware and we are making a big deal about this because we are concerned for human safety," wrote the employee, whose name was redacted from the records.

PCRM has raised concerns about Neuralink in the past. Last year, it wrote to federal officials about alleged animal-welfare issues during Neuralink’s research partnership with UC Davis, citing another set of records it obtained. A federal prosecutor in the Northern District of California referred PCRM's complaint to the USDA Inspector General, which later launched the federal probe into Neuralink, Reuters previously reported.

During its partnership with UC Davis, Neuralink grew frustrated with what it regarded as the slow pace of testing on primates, current and former company employees told Reuters, and has since built out extensive in-house animal testing facilities. The company has missed deadlines set by Musk to proceed to human trials, however. His pressure on Neuralink’s staff to make progress contributed to mistakes plaguing some experiments, Reuters reported.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.